Guggenheim raised the firm’s price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the “promising” preliminary readout from the ORX750 CRYSTAL-1 Ph2a study as well as the “relatively underwhelming” results from alixorexton in NT2 that were reported by Alkermes (ALKS).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals Announces Underwriting Agreement for ADS Offering
- Centessa Pharmaceuticals: Promising Market Position with ORX750’s Superior Efficacy and Potential
- Morgan Stanley sees Centessa’s ORX750 as ‘best-in-class’ after competitor data
- Midday Fly By: AMD sees acceleration, IBM unveils quantum processor
- Centessa rises 14.0%